OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

Brief summary (registry, in English)

The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).

What you commit to

• Study type: Interventional · Phase 3
• Planned participants: 11000
• From 22 Aug 2025 to the primary completion date, 20 Oct 2031
• 252 sites in 3 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 50 years to 105 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (252)

Sites in registry order. Pick your city on the disease page to sort them by distance.